AMO Pharma Secures Global Regulatory Green Light for cDM1 Study

The company will utilize hospitalization rates as the primary efficacy endpoint, a move intended to address the significant medical burden placed on patients and caregivers by the disorder’s frequent, life-threatening complications. To ensure the trial captures the full scope of the disease, secondary measures will include a series of functional assessments designed to track progression across a condition that often presents with widely varying clinical symptoms.

Dr. Mike Snape, chief executive officer at AMO Pharma, noted that the alignment with international regulators allows the company to accelerate its planning and execution phases. The trial design also aligns with language recently adopted in the FY27 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations bill. While the regulatory feedback is not legally binding, it provides a clear framework for the upcoming study, with further updates on trial initiation expected in the third quarter of 2026.